Source comparison
Comparison: PT-141 vs PDE5 Inhibitors and Other Arousal Agents
PT-141 (bremelanotide) 45–90 min (central arousal); 90–120 min (genital) 2–3 hours 6–12 hours sustained Melanocortin-4 receptors in hypothalamus. Increases sexual desire before physical arousal No. Induces spontaneous desire independent of external stimulation
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- 45–90 min (central arousal); 90–120 min (genital)
- 2–3 hours
- 6–12 hours sustained
- Melanocortin-4 receptors in hypothalamus. Increases sexual desire before physical arousal
- No. Induces spontaneous desire independent of external stimulation
- Best for low baseline desire (HSDD) where psychological arousal is the bottleneck, not genital response
- Sildenafil (Viagra)
- 30–60 min
- 1 hour
- 4–6 hours
- PDE5 enzyme in genital tissue. Increases nitric oxide-mediated blood flow
- Yes. Requires active sexual stimulation to produce effect
- Best for arousal disorders where desire exists but genital engorgement is impaired (arousal without lubrication/sensation)
- Flibanserin (Addyi)
- Chronic dosing (4–8 weeks daily)
- No acute peak. Baseline shift over weeks
- Continuous (daily dosing)
- Serotonin 5-HT1A agonist / 5-HT2A antagonist. Modulates dopamine/norepinephrine balance
- No. Alters baseline neurotransmitter tone to increase spontaneous desire
- Best for chronic low desire where daily intervention is acceptable; not suitable for 'as-needed' scenarios
- Topical testosterone (off-label)
- Days to weeks (chronic use)
- Weeks 2–4
- Continuous (chronic dosing)
- Androgen receptors. Increases baseline libido and clitoral sensitivity
- No. Raises baseline arousal potential rather than triggering acute episodes
- Best for testosterone deficiency; requires monitoring for virilization side effects